Hemophilia A

Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients

BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis

Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients

BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis

Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients

Generation Bio Hits 52-Week Low After Preclinical Data From Hemophilia A Program

Sigilon Therapeutics Issues An Update On Its Early-Stage Hemophilia Study

Generation Bio Hits 52-Week Low After Preclinical Data From Hemophilia A Program

Sigilon Therapeutics Issues An Update On Its Early-Stage Hemophilia Study

Centessa Stock Surges On Positive Data From Hemophilia Candidate

BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy

Hemophilia A Recent News

Spark Therapeutics' Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression

BioMarin Unveils News Data From Late-Stage Hemophilia A Gene Therapy Candidate

Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A

According to Roche Holding AG's (OTC: RHHBY) Genentech division, new data from a phase 3b study reinforces the safety profile of blockbuster hemophilia A treatment Hemlibra.

BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22

Serious Adverse Event Triggers FDA Clinical Hold On Sigilon Therapeutics' Hemophilia A Trial, Shares Drop

EMA Grants BioMarin's Request For Speedy Review of Hemophilia A Gene Therapy

Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit

Newly Launched Centessa Pharmaceuticals Plans $100M Debut On NASDAQ

BioMarin's Hemophilia Gene Therapy Scores RMAT Designation In US

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) desig

Baird Buying Ultragenyx And BioMarin